From old alkylating agents to new minor groove binders

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 1, 2014, Pages 43-61

  Puyo, Stéphane ^a   Montaudon, Danièle ^a   Pourquier, Philippe ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Alkylating agents; DNA adducts; DNA crosslinks; DNA repair; O6 methylguanine

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CHLORMETHINE; CONGOCIDINE; CYCLOPHOSPHAMIDE; DISTAMYCIN A; ESTRAMUSTINE; HYDRAZINE DERIVATIVE; IFOSFAMIDE; ILLUDIN M; ILLUDIN S; MITOMYCIN; NITROSOUREA DERIVATIVE; PLATINUM DERIVATIVE; TETRAHYDROISOQUINOLINE; TRABECTEDIN; TRIAZENE DERIVATIVE; ALTRETAMINE; ANTIINFECTIVE AGENT; BENDAMUSTINE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; DACARBAZINE; FOTEMUSTINE; GLUFOSFAMIDE; LOMUSTINE; MAFOSFAMIDE; MELPHALAN; NIMUSTINE; OXALIPLATIN; PROCARBAZINE; STREPTOZOCIN; TEMOZOLOMIDE; THIOTEPA; THYMINE; TROFOSFAMIDE; UNINDEXED DRUG;

BLADDER TOXICITY; CARBAMOYLATION; DNA ALKYLATION; DNA CROSS LINKING; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; IONIZATION; NEPHROTOXICITY; NEUROTOXICITY; NUCLEOPHILICITY; REVIEW; SARCOMA; SOLID TUMOR; ASTROCYTOMA; BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; CANCER PALLIATIVE THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; CYTOTOXICITY; DRUG BINDING; DRUG EFFICACY; ESOPHAGUS CANCER; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEMATOLOGIC TUMOR; LEUKEMIA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE MYELOMA; MYELOMA; NEOPLASM; NEUROENDOCRINE TUMOR; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; RECTUM CANCER; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TESTIS CANCER; TOXICITY;

ALKYLATING AGENTS; DNA ADDUCTS; DNA CROSSLINKS; DNA REPAIR; O6-METHYLGUANINE;

ALKYLATING AGENTS; ALKYLATION; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; DNA; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84890861351     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.07.006     Document Type: Review

References (119)

1. Adair F.E., Bagg H.J. Experimental, clinical studies on the treatment of cancer by dichlorethylsulphide (mustard gas). Annals of Surgery 1931, 93:190-199.
2. Goodman L.S., Wintrobe M.M., Dameshek W., et al. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. Journal of the American Medical Association 1946, 132:126-132.
3. Holland J.F., Frei E. Holland-Frei cancer medicine 2003, BC Decker Inc., Hamilton, ON. 6th ed.
4. Brion J.-D. Agents Alkylants: Généralités Médicaments antitumoraux et perspectives dans le traitement des cancers 2003, 43-52. TEC & DOC, Paris.
5. Colvin M., Chabner B.A. Alkylating agents in cancer chemotherapy: principles and practice 1990, 276-313. Lippincott, Philadelphia. B.A. Chabner, J.M. Collins (Eds.).
6. Beranek D.T. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutation Research 1990, 231:11-30.
7. Drablos F., Feyzi E., Aas P.A., et al. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst) 2004, 3:1389-1407.
8. Shrivastav N., Li D., Essigmann J.M. Chemical biology of mutagenesis and DNA repair: cellular responses to DNA alkylation. Carcinogenesis 2009, 31:59-70.
9. Shooter K.V., Howse R., Shah S.A., Lawley P.D. The molecular basis for biological inactivation of nucleic acids. The action of methylating agents on the ribonucleic acid-containing bacteriophage R17. Biochemical Journal 1974, 137:303-312.
10. Pullman A., Pullman B. Molecular electrostatic potential of the nucleic acids. Quarterly Reviews of Biophysics 1981, 14:289-380.
11. Mishina Y., Duguid E.M., He C. Direct reversal of DNA alkylation damage. Chemical Reviews 2006, 106:215-232.
12. Gates K.S. An overview of chemical processes that damage cellular DNA: spontaneous hydrolysis, alkylation, and reactions with radicals. Chemical Research in Toxicology 2009, 22:1747-1760.
13. Tudek B., Boiteux S., Laval J. Biological properties of imidazole ring-opened N7-methylguanine in M13mp18 phage DNA. Nucleic Acids Research 1992, 20:3079-3084.
14. Fronza G., Gold B. The biological effects of N3-methyladenine. Journal of Cellular Biochemistry 2004, 91:250-257.
15. Margison G.P., Santibanez Koref M.F., Povey A.C. Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis 2002, 17:483-487.
16. Bignami M., O'Driscoll M., Aquilina G., Karran P. Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutation Research 2000, 462:71-82.
17. Kaina B., Ochs K., Grosch S., et al. BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis. Progress in Nucleic Acid Research and Molecular Biology 2001, 68:41-54.
18. Baumann R.P., Shyam K., Penketh P.G., Remack J.S., Brent T.P., Sartorelli A.C. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemotherapy and Pharmacology 2004, 53:288-295. [Epub 2003 Dec 17].
19. Frederick A.M., Davis M.L., Rice K.P. Inhibition of human DNA polymerase beta activity by the anticancer prodrug Cloretazine. Biochemical and Biophysical Research Communications 2009, 378:419-423. [Epub Nov 21]. 10.1016/j.bbrc.2008.11.042.
20. Couquelet J. Moutardes à l'azote, Médicaments antitumoraux et perspectives dans le traitement des cancers 2003, 53-71. TEC & DOC, Paris.
21. Povirk L.F., Shuker D.E. DNA damage and mutagenesis induced by nitrogen mustards. Mutation Research 1994, 318:205-226.
22. Giraud B., Hebert G., Deroussent A., Veal G.J., Vassal G., Paci A. Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opinion on Drug Metabolism & Toxicology 2010, 6:919-938.
23. Huet J., Uriac P. Oxazophorines: cyclophosphamide et analogues. Médicaments antitumoraux et perspectives dans le traitement des cancers 2003, 85-116. TEC & DOC, Paris.
24. Latz D., Nassar N., Frank R. Trofosfamide in the palliative treatment of cancer: a review of the literature. Onkologie 2004, 27:572-576.
25. Lacombe D. Glufosfamide: can we improve the process of anticancer agent development. Expert Opinion on Investigational Drugs 2012, 21:749-754.
26. Maanen M.J., Smeets C.J., Beijnen J.H. Chemistry, pharmacology and pharmacokinetics of N,N',N'-triethylenethiophosphoramide (ThioTEPA). Cancer Treatment Reviews 2000, 26:257-268.
27. Laronze J.-Y., Laronze J. Ethylènes imines. Médicaments antitumoraux et perspectives dans le traitement des cancers 2003, 73-83. TEC & DOC, Paris.
28. Giorgi-Renault S., Mitomycine C. Médicaments antitumoraux et perspectives dans le traitement des cancers 2003, 127-149. TEC & DOC, Paris.
29. Iyer V.N., Szybalski W. Mitomycins and porfiromycin chemical mechanism of activation and cross-linking of DNA. Science 1964, 145:55-58.
30. Dorr R.T., Bowden G.T., Alberts D.S., Liddil J.D. Interactions of mitomycin C with mammalian DNA detected by alkaline elution. Cancer Research 1985, 45:3510-3516.
31. Borowy-Borowski H., Lipman R., Tomasz M. Recognition between mitomycin C and specific DNA sequences for cross-link formation. Biochemistry 1990, 29:2999-3006.
32. Schepartz S.A. Early history and development of the nitrosoureas. Cancer Treatment Reports 1976, 60:647-649.
33. Brion J.-D. Nitrosourées Médicaments antitumoraux et perspectives dans le traitement des cancers 2003, 151-176. TEC & DOC, Paris.
34. Gnewuch C.T., Sosnovsky G. A critical appraisal of the evolution of N-nitrosoureas as anticancer drugs. Chemical Reviews 1997, 97:829-1014.
35. Schabel F.M., Johnston T.P., Mc C.G., Montgomery J.A., Laster W.R., Skipper H.E. Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. Cancer Research 1963, 23:725-733.
36. Colvin M., Brundrett R.B., Cowens W., Jardine I., Ludlum D.B. A chemical basis for the antitumor activity of chloroethylnitrosoureas. Biochemical Pharmacology 1976, 25:695-699.
37. Kohn K.W. Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Research 1977, 37:1450-1454.
38. Sariban E., Erickson L.C., Kohn K.W. Effects of carbamoylation on cell survival and DNA repair in normal human embryo cells (IMR-90) treated with various 1-(2-chloroethyl)-1-nitrosoureas. Cancer Research 1984, 44:1352-1357.
39. Berque-Bestel I. Sulfonylalcanes Médicaments antitumoraux et perspectives dans le traitement des cancers 2003, 117-126. TEC & DOC, Paris.
40. Ponti M., Souhami R.L., Fox B.W., Hartley J.A. DNA interstrand crosslinking and sequence selectivity of dimethanesulphonates. British Journal of Cancer 1991, 63:743-747.
41. Uriac P., Huet J. Dacarbazine et témozolomide. Médicaments antitumoraux et perspectives dans le traitement des cancers 2003, 177-214. TEC & DOC, Paris.
42. Newlands E.S., Stevens M.F., Wedge S.R., Wheelhouse R.T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treatment Reviews 1997, 23:35-61.
43. Uriac P., Huet J., Procarbazine Médicaments antitumoraux et perspectives dans le traitement des cancers 2003, 215-223. TEC & DOC, Paris.
44. Erikson J.M., Tweedie D.J., Ducore J.M., Cytotoxicity Prough R.A. DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Research 1989, 49:127-133.
45. Swaffar D.S., Horstman M.G., Jaw J.Y., et al. Methylazoxyprocarbazine, the active metabolite responsible for the anticancer activity of procarbazine against L1210 leukemia. Cancer Research 1989, 49:2442-2447.
46. Fong L.Y., Bevill R.F., Thurmon J.C., Magee P.N. DNA adduct dosimetry and DNA repair in rats and pigs given repeated doses of procarbazine under conditions of carcinogenicity and human cancer chemotherapy respectively. Carcinogenesis 1992, 13:2153-2159.
47. Nuhrich A., Varache-Lembège M. Complexes du platine. Médicaments antitumoraux et perspectives dans le traitement des cancers 2003, 226-282. TEC & DOC, Paris.
48. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacology & Therapeutics 1987, 34:155-166.
49. Chaney S.G., Campbell S.L., Bassett E., Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Critical Reviews in Oncology/Hematology 2005, 53:3-11.
50. Raymond E., Faivre S., Chaney S., Woynarowski J., Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Molecular Cancer Therapeutics 2002, 1:227-235.
51. Saris C.P., van de Vaart P.J., Rietbroek R.C., Blommaert F.A. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996, 17:2763-2769.
52. Shen D.W., Pouliot L.M., Hall M.D., Gottesman M.M. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacological Reviews 2012, 64:706-721.
53. D'Incalci M., Sessa C. DNA minor groove binding ligands: a new class of anticancer agents. Expert Opinion on Investigational Drugs 1997, 6:875-884.
54. Cai X., Gray P.J., Von Hoff D.D. DNA minor groove binders: back in the groove. Cancer Treatment Reviews 2009, 35:437-450. [Epub Mar 27]. 10.1016/j.ctrv.2009.02.004.
55. Khan G.S., Shah A., Zia ur R., Barker D. Chemistry of DNA minor groove binding agents. Journal of Photochemistry and Photobiology B 2012, 115:105-118.
56. Broggini M., Ponti M., Ottolenghi S., D'Incalci M., Mongelli N., Mantovani R. Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements. Nucleic Acids Research 1989, 17:1051-1059.
57. Dorn A., Affolter M., Muller M., Gehring W.J., Leupin W. Distamycin-induced inhibition of homeodomain-DNA complexes. EMBO Journal 1992, 11:279-286.
58. Bellorini M., Moncollin V., D'Incalci M., Mongelli N., Mantovani R. Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. Nucleic Acids Research 1995, 23:1657-1663.
59. Broggini M., Coley H.M., Mongelli N., et al. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Research 1995, 23:81-87.
60. Broggini M., Erba E., Ponti M., et al. Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Research 1991, 51:199-204.
61. Wyatt M.D., Lee M., Garbiras B.J., Souhami R.L., Hartley J.A. Sequence specificity of alkylation for a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size: evidence for increased cytotoxicity with enhanced sequence specificity. Biochemistry 1995, 34:13034-13041.
62. Fedier A., Fowst C., Tursi J., et al. Brostallicin (PNU-166196)-a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells. British Journal of Cancer 2003, 89:1559-1565.
63. Lorusso D., Mainenti S., Pietragalla A., et al. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opinion on Investigational Drugs 2009, 18:1939-1946. doi:10.517/13543780903401284.
64. Iyer P., Srinivasan A., Singh S.K., et al. Synthesis and characterization of DNA minor groove binding alkylating agents. Chemical Research in Toxicology 2012, 2012:26.
65. Boger D.L., Johnson D.S. CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:3642-3649.
66. Rayburn E., Wang W., Li M., et al. Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemotherapy and Pharmacology 2012, 69:1423-1431.
67. Wolfe A.L., Duncan K.K., Parelkar N.K., Weir S.J., Vielhauer G.A., Boger D.L. A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct. Journal of Medicinal Chemistry 2012, 55:5878-5886.
68. Ghielmini M., Bosshard G., Capolongo L., et al. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. British Journal of Cancer 1997, 75:878-883.
69. Schobert R., Knauer S., Seibt S., Biersack B. Anticancer active illudins: recent developments of a potent alkylating compound class. Current Medicinal Chemistry 2011, 18:790-807.
70. Baekelandt M. Irofulve; (MGI Pharma). Current Opinion in Investigational Drugs 2002, 3:1517-1526.
71. Tanasova M., Sturla S.J. Chemistry and biology of acylfulvenes: sesquiterpene-derived antitumor agents. Chemical Reviews 2012, 112:3578-3610.
72. Gong J., Vaidyanathan V.G., Yu X., Kensler T.W., Peterson L.A., Sturla S.J. Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent. Journal of the American Chemical Society 2007, 129:2101-2111. [Epub 007 Jan 27].
73. Koeppel F., Poindessous V., Lazar V., Raymond E., Sarasin A., Larsen A.K. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clinical Cancer Research 2004, 10:5604-5613.
74. Escargueil A.E., Poindessous V., Soares D.G., Sarasin A., Cook P.R., Larsen A.K. Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells. Journal of Cell Science 2008, 121:1275-1283.
75. Rinehart K.L., Gloer J.B., Hughes R.G., et al. Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate. Science 1981, 212:933-935.
76. Sakai R., Rinehart K.L., Guan Y., Wang A.H. Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:11456-11460.
77. Cuevas C., Francesch A. Development of Yondelis (trabectedin, ET-743), A semisynthetic process solves the supply problem. Natural Product Reports 2009, 26:322-337. [Epub 2009 Jan 7]. 10.1039/b808331m.
78. D'Incalci M., Galmarini C.M. A review of trabectedin (ET-743): a unique mechanism of action. Molecular Cancer Therapeutics 2010, 9:2157-2163. [Epub 2010 Jul 20].
79. Pommier Y., Kohlhagen G., Bailly C., Waring M., Mazumder A., Kohn K.W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996, 35:13303-13309.
80. Zewail-Foote M., Hurley L.H. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. Journal of Medicinal Chemistry 1999, 42:2493-2497.
81. Hurley L.H., Zewail-Foote M. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability. Advances in Experimental Medicine and Biology 2001, 500:289-299.
82. Bonfanti M., La Valle E., Fernandez Sousa Faro J.M., et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anti-Cancer Drug Design 1999, 14:179-186.
83. Minuzzo M., Marchini S., Broggini M., Faircloth G., D'Incalci M., Mantovani R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:6780-6784.
84. Jin S., Gorfajn B., Faircloth G., Scotto K.W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:6775-6779.
85. Synold T.W., Dussault I., Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Medicine 2001, 7:584-590.
86. Minuzzo M., Ceribelli M., Pitarque-Marti M., et al. Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Molecular Pharmacology 2005, 68:1496-1503. [Epub 2005 Jun 16].
87. Martinez E.J., Corey E.J., Owa T. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chemistry & Biology 2001, 8:1151-1160.
88. Erba E., Cavallaro E., Damia G., et al. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring. Oncology Research 2004, 14:579-587.
89. Soares D.G., Machado M.S., Rocca C.J., et al. Trabectedin and its c subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Molecular Cancer Therapeutics 2011, 2011:5.
90. Guirouilh-Barbat J., Redon C., Pommier Y. Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Molecular Biology of the Cell 2008, 19:3969-3981. [Epub 2008 Jul 16].
91. Soares D.G., Escargueil A.E., Poindessous V., et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:13062-13067. [Epub 2007 Jul 26].
92. Takebayashi Y., Pourquier P., Zimonjic D.B., et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nature Medicine 2001, 7:961-966.
93. Damia G., Silvestri S., Carrassa L., et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. International Journal of Cancer 2001, 92:583-588.
94. Herrero A.B., Martin-Castellanos C., Marco E., Gago F., Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Research 2006, 66:8155-8162.
95. Tavecchio M., Simone M., Erba E., et al. Role of homologous recombination in trabectedin-induced DNA damage. European Journal of Cancer 2008, 44:609-618. [Epub Feb 19]. 10.1016/j.ejca.2008.01.003.
96. Guirouilh-Barbat J., Antony S., Pommier Y. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Molecular Cancer Therapeutics 2009, 8:2007-2014. [Epub 9 Jul 7].
97. Allavena P., Signorelli M., Chieppa M., et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Research 2005, 65:2964-2971.
98. Germano G., Frapolli R., Simone M., et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Research 2010, 70:2235-2244.
99. Germano G., Frapolli R., Belgiovine C., et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013, 23:249-262.
100. Sehouli J., Alfaro V., Gonzalez-Martin A. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. Annals of Oncology 2011, 2011:6.
101. Stevens E.V., Nishizuka S., Antony S., et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Molecular Cancer Therapeutics 2008, 7:10-18. [Epub 2008 Jan 9].
102. Romano M., Frapolli R., Zangarini M., et al. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis(R) (PM00104). International Journal of Cancer 2013, 2013:28213.
103. Kaina B., Christmann M., Naumann S., Roos W.P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007, 6:1079-1099. [Epub 2007 May 7].
104. Kaina B., Margison G.P., Christmann M. Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cellular and Molecular Life Sciences 2010, 67:3663-3681.
105. Dolan M.E., Mitchell R.B., Mummert C., Moschel R.C., Pegg A.E. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Research 1991, 51:3367-3372.
106. Duncan T., Trewick S.C., Koivisto P., Bates P.A., Lindahl T., Sedgwick B. Reversal of DNA alkylation damage by two human dioxygenases. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:16660-16665. [Epub 2002 Dec 16].
107. Wilson D.M., Barsky D. The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. Mutation Research 2001, 485:283-307.
108. Robertson A.B., Klungland A., Rognes T., Leiros I. DNA repair in mammalian cells: Base excision repair: the long and short of it. Cellular and Molecular Life Sciences 2009, 66:981-993.
109. Liu L., Gerson S.L. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Current Opinion in Investigational Drugs 2004, 5:623-627.
110. Wilson S.H., Beard W.A., Shock D.D., et al. Base excision repair and design of small molecule inhibitors of human DNA polymerase beta. Cellular and Molecular Life Sciences 2010, 67:3633-3647.
111. Krishnakumar R., Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Molecular Cell 2010, 39:8-24.
112. Curtin N.J., Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Molecular Aspects of Medicine 2013, [in press]. 10.1016/j.mam.2013.01.006.
113. Calabrese C.R., Almassy R., Barton S., et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. Journal of the National Cancer Institute 2004, 96:56-67.
114. Daniel R.A., Rozanska A.L., Mulligan E.A., et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British Journal of Cancer 2010, 103:1588-1596.
115. Miknyoczki S.J., Jones-Bolin S., Pritchard S., et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Molecular Cancer Therapeutics 2003, 2:371-382.
116. Thomas H.D., Calabrese C.R., Batey M.A., et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Molecular Cancer Therapeutics 2007, 6:945-956.
117. Rouleau M., Patel A., Hendzel M.J., Kaufmann S.H., Poirier G.G. PARP inhibition: PARP1 and beyond. Nature Reviews Cancer 2010, 10:293-301. [Epub 2010 Mar 4].
118. Plummer R., Lorigan P., Steven N., et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemotherapy and Pharmacology 2013, 71(5):1191-1199.
119. Quiros S., Roos W.P., Kaina B. Rad51 and BRCA2-new molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS ONE 2011, 6:2.